Sana Biotechnology, Inc. (SANA) Stock Price & Analysis

Sana Biotechnology, Inc. (SANA) fell 1.79% to USD 3.85 as of September 8, 2026 at 07:37 UTC, according to Nexqual real-time market data.

SANA last closed at USD 3.85; the session ranged USD 3.81–3.92 on volume of 1,239,920 shares. Market capitalization is —, with a 52-week range of USD 2.61–6.55 (NMS). Source: Nexqual, September 8, 2026 at 07:37 UTC.

Key Statistics (as of September 8, 2026 at 07:37 UTC)

Technical Analysis (SANA)

Nexqual's technical model rates SANA "STRONG BUY" based on 5 bullish and 0 bearish signals across 128 daily candles, as of September 8, 2026 at 07:37 UTC.

From Sana Biotechnology, Inc.'s Latest SEC 10-K Filing (filed 2026-03-03)

Key Strengths & Strategy (as disclosed to the SEC)

• We expect to submit an IND for SC451 and begin our Phase 1 trial as early as this year. 6   With respect to our in vivo cell engineering research efforts, we have advanced from our earlier SG299 in vivo CAR T candidate to an improved next-generation product candidate, SG293, both of which use our proprietary fusogen-based delivery platform.
• We have built significant internal capabilities across a wide range of areas focused on solving the most critical limitations in engineering cells including: • Stem Cell and Disease Biology .
• To demonstrate applicability in the context of the autoimmunity seen in people with T1D, we developed a proprietary mouse model in-house with human immune cells from a T1D patient.
• The safety data, secondary endpoints, dosing rationale, clinical outcomes, and immune analysis from the treated patient are discussed below in the section titled "Pancreatic Islet Cell Program." 9   In vivo CD19-Directed CAR T Cells SG293 Our in vivo CAR T pipeline has advanced beyond our earlier constructs, such as SG299, to our next-generation product candidate, SG293, which leverages our proprietary fusogen delivery platform to enable direct, in-patient generation of CAR T cells.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 07:37 UTC. This page is informational and not investment advice.